Stay updated with breaking news from Urgency Numeric Rating Scale. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The past year has seen a multitude of FDA approvals, ranging from IL-23 and JAK inhibitors to biologics and subcutaneous treatment administrations, that have helped redefine what it means to treat IBD.
Eli Lilly and Company announced the FDA approval of mirikizumab (Omvoh) for moderately and severely active ulcerative colitis in adults on October 26, 2023.
Mirikizumab-mrkz (Omvoh; Eli Lilly and Company) is the first IL-23p19 antagonist approved for adult patients with moderately to severely active ulcerative colitis.
Findings were presented in an abstract at ACG 2023, highlighting the importance of addressing bowel urgency in patients with ulcerative colitis.
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh™ (mirikizumab-mrkz)...